Enveda, an AI drugmaker, banks $311M in venture funding
The biotech startup said the new capital will advance three clinical-stage candidates and expand its PRISM platform, after early trial data showed promise in eczema and obesity.
10 Articles
10 Articles
TechCrunch
BizTocEnveda secures $311M to bring more nature-derived AI drugs into clinical trials
The round valued the AI biotech at $2 billion. It is currently testing drugs that treat skin conditions and preserve weight loss after stopping GLP-1s.
Biotech company Enveda has raised $311 million in a Series E round led by Catalio Capital Management. According to Techcrunch, the company is valued at $2 billion, equivalent to SEK 19.8 billion, double what it was twelve months ago.
Enveda, a biotechnology startup that combines artificial intelligence with plant and microbe compounds, captured $311 million in an E Series and reached a $2 billion valuation. The company seeks to use that capital to advance several candidates to clinical trials, in a career where programs developed with AI support still have to demonstrate their safety and efficacy in patients.
Crypto Briefing
Cryptocurrency News | Cryptocurrency Prices | Market CapEnveda secures $311M to advance nature-derived AI drugs into trials
Enveda's funding boost could accelerate AI-driven drug discovery, potentially transforming pharmaceutical development and enhancing global healthcare.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
